| scholarly article | Q13442814 |
| P50 | author | Jonathan D Schofield | Q38548429 |
| P2093 | author name string | Handrean Soran | |
| Jan Ho | |||
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study | Q28287744 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| Progress and challenges in translating the biology of atherosclerosis | Q29619982 | ||
| Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
| Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study | Q30276065 | ||
| Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification | Q33589073 | ||
| Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus | Q33590908 | ||
| Dysfunctional HDL as a diagnostic and therapeutic target | Q33604003 | ||
| Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. | Q53786578 | ||
| Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q56979722 | ||
| Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus | Q57452493 | ||
| Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus | Q57452495 | ||
| Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study | Q57943431 | ||
| Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia | Q58480971 | ||
| SGLT inhibitor adjunct therapy in type 1 diabetes | Q58718282 | ||
| Glycemic Control and Excess Mortality in Type 1 Diabetes | Q59587753 | ||
| Lipoprotein(a) as a Predictor of Cardiovascular Disease in a Prospectively Followed Cohort of Patients With Type 1 Diabetes | Q61817211 | ||
| The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification | Q61917117 | ||
| Serum high density lipoprotein cholesterol subfractions in type I (insulin-dependent) diabetes mellitus | Q70307600 | ||
| The effect of continuous subcutaneous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type I diabetes mellitus | Q71727727 | ||
| Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration | Q72139612 | ||
| Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging | Q72387377 | ||
| Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation | Q74651672 | ||
| Inhibition by cholesterol oxides of NO release from human vascular endothelial cells | Q74794160 | ||
| Impact of physical activity on cardiovascular risk factors in children with type 1 diabetes: a multicenter study of 23,251 patients | Q80236869 | ||
| Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease | Q81780779 | ||
| Severe forms of retinopathy predict the presence of subclinical atherosclerosis in type 1 diabetes subjects | Q82099983 | ||
| High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database | Q82985834 | ||
| Ezetimibe plus a Statin after Acute Coronary Syndromes | Q86410641 | ||
| Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes | Q89371059 | ||
| Professional Practice Committee: Standards of Medical Care in Diabetes-2018 | Q89584596 | ||
| Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus | Q90759676 | ||
| Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q90959912 | ||
| Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study | Q92203683 | ||
| Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study | Q93349652 | ||
| Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort | Q33781706 | ||
| Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? | Q33833060 | ||
| Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial | Q33835341 | ||
| Hypoglycemia, diabetes, and cardiovascular events | Q33873251 | ||
| Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes | Q33905277 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus | Q34070803 | ||
| Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus | Q34070807 | ||
| Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association | Q34219439 | ||
| Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes | Q34355350 | ||
| Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial | Q34361001 | ||
| Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study | Q34440576 | ||
| Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. | Q34644351 | ||
| Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis | Q34660044 | ||
| Metabolic origins and clinical significance of LDL heterogeneity | Q34863756 | ||
| Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials | Q34982751 | ||
| Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies | Q35043852 | ||
| Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study | Q35166512 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? | Q35184844 | ||
| High-density lipoprotein cholesterol in diabetes: is higher always better? | Q35302241 | ||
| Predicting major outcomes in type 1 diabetes: a model development and validation study | Q35446651 | ||
| Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study | Q35765550 | ||
| 'Lipoproteins, glycoxidation and diabetic angiopathy'. | Q35877289 | ||
| Insulin treatment and cardiovascular disease; friend or foe? A point of view. | Q36014899 | ||
| Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus | Q36054342 | ||
| Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study | Q36078938 | ||
| Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technology--New Possibility to Decrease Cardiovascular Risk? | Q36328989 | ||
| Progression of coronary artery calcium in type 1 diabetes mellitus | Q36392791 | ||
| Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes | Q36513259 | ||
| Type 1 diabetes and coronary artery disease | Q36634829 | ||
| Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up | Q36820594 | ||
| Risk Factors for Cardiovascular Disease in Type 1 Diabetes | Q36820764 | ||
| Diabetes and Hypertension: A Position Statement by the American Diabetes Association. | Q48199922 | ||
| Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes | Q48226528 | ||
| Sodium-glucose co-transporter 2 (SGLT2) inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials | Q49928443 | ||
| A Shift in ApoM/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM/S1P Complex. | Q51068455 | ||
| Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. | Q51334840 | ||
| Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. | Q51582274 | ||
| Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects | Q51606098 | ||
| Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. | Q51789971 | ||
| The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. | Q52583989 | ||
| Cardiovascular actions of insulin | Q36831533 | ||
| Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group | Q36900139 | ||
| Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations | Q37011769 | ||
| Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study | Q37090802 | ||
| Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus | Q37239783 | ||
| Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study | Q37331337 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Hyperglycemia and glycation in diabetic complications. | Q37505050 | ||
| Vascular actions of insulin with implications for endothelial dysfunction | Q37505788 | ||
| Susceptibility of LDL and its subfractions to glycation | Q37898480 | ||
| Role of oxidatively modified LDL in atherosclerosis | Q37978587 | ||
| High-density lipoprotein cholesterol raising: does it matter? | Q38111980 | ||
| Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). | Q38199288 | ||
| Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. | Q38347326 | ||
| Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
| Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial | Q38725515 | ||
| Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: A randomized open-label crossover trial. | Q38874435 | ||
| Association between adherence to dietary recommendations and high-sensitivity C-reactive protein level in type 1 diabetes | Q38941904 | ||
| Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus | Q39222822 | ||
| Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine. | Q39988897 | ||
| The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study | Q40121355 | ||
| Deficiencies of cardiovascular risk prediction models for type 1 diabetes | Q40302948 | ||
| LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes | Q41188538 | ||
| Glycemic variability predicts inflammation in adolescents with type 1 diabetes | Q41276954 | ||
| Treatment of dyslipoproteinaemia in diabetes mellitus | Q41480609 | ||
| Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study | Q41709013 | ||
| Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study | Q42290483 | ||
| A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis | Q42524986 | ||
| Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. | Q43034811 | ||
| Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study | Q43435231 | ||
| Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study | Q43492278 | ||
| Genetically elevated lipoprotein(a) and increased risk of myocardial infarction | Q44238417 | ||
| Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 | ||
| Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study | Q44745070 | ||
| Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial | Q44847105 | ||
| Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. | Q45068001 | ||
| Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes | Q45285721 | ||
| Exercise training improves physical fitness and vascular function in children with type 1 diabetes. | Q46199314 | ||
| Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis | Q46585406 | ||
| Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis | Q46810855 | ||
| Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study | Q47176475 | ||
| Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. | Q47442728 | ||
| P433 | issue | 3 | |
| P921 | main subject | type-1 diabetes | Q124407 |
| P304 | page(s) | 773-789 | |
| P577 | publication date | 2019-04-19 | |
| P1433 | published in | Diabetes Therapy | Q26853803 |
| P1476 | title | Cardiovascular Risk in Type 1 Diabetes Mellitus. | |
| P478 | volume | 10 |
| Q92328545 | Coagulatory Defects in Type-1 and Type-2 Diabetes |
| Q91717973 | Insulin resistance is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes |
| Q92673090 | Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis |
Search more.